Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 10% - What's Next?

Key Points

• Shares of Damora Therapeutics (NASDAQ:DMRA) fell about 10% on Thursday, trading as low as $18.50 and last at $19.04 on volume of ~241,599 shares (≈10% above the average daily volume).
• Analysts maintain a consensus Moderate Buy rating with a consensus price target of $43.67, driven by recent coverage setting targets in the roughly $40–$46 range.
• Damora is a clinical‑stage biotech with a market cap of about $1.11B, developing galectin‑3 and LOXL2 inhibitors (lead programs GB0139 inhaled and GB1211 oral); the stock shows a negative P/E (−1.58) and 50‑day/200‑day moving averages of $27.00/$18.79.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report)'s stock price dropped 10% during trading on Thursday . The stock traded as low as $18.50 and last traded at $19.04. Approximately 241,599 shares changed hands during trading, an increase of 10% from the average daily volume of 218,704 shares. The stock had previously closed at $21.15.

Analyst Upgrades and Downgrades

DMRA has been the subject of a number of analyst reports. UBS Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a "buy" rating and a $45.00 target price for the company. Guggenheim reaffirmed a "buy" rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a report on Monday, February 2nd. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a "hold" rating in a research report on Friday, January 9th. Finally, Leerink Partners started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They set an "outperform" rating and a $46.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.67.

Damora Therapeutics, Inc. Common Stock Stock Performance

The stock has a market cap of $1.11 billion, a P/E ratio of -1.58 and a beta of 1.42. The firm has a 50-day moving average price of $27.00 and a 200-day moving average price of $18.79.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $76,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth about $49,000. Connective Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth about $100,000. Sigma Planning Corp purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $334,000. Finally, Geode Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. Hedge funds and other institutional investors own 14.20% of the company's stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.